Pharmaceuticals company AbbVie, Inc. (NYSE: ABBV) on Friday reported a decline in earnings for the third quarter of fiscal 2025, despite an increase in revenue. The company also raised its full-year earnings guidance.
Net revenues increased to $15.8 billion in the September quarter from $14.5 billion in the corresponding period of fiscal 2024.
Net earnings, on an adjusted basis, declined to $1.86 per share in the third quarter from $3.0 per share in the year-ago quarter. Net income attributable to the company, on a reported basis, was $186 million or $0.10 per share in Q3, compared to $1.56 billion or $0.88 per share last year.
The management raised its full-year 2025 adjusted earnings guidance range from $10.38-0.58 per share to $10.61-$10.65 per share. The revised guidance includes an unfavorable impact of $2.05 per share related to acquired IPR&D and milestones expense incurred year-to-date through the third quarter.
The post ABBV Earnings: A snapshot of AbbVie’s Q3 2025 report first appeared on AlphaStreet.
—
Blog powered by G6
Disclaimer! A guest author has made this post. G6 has not checked the post. its content and attachments and under no circumstances will G6 be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your use of or inability to use this website or any websites linked to it, or from your reliance on the information and material on this website, even if the G6 has been advised of the possibility of such damages in advance.
For any inquiries, please contact [email protected]
